logo
Removing fluoride from public drinking water may lead to millions more cavities in US children, study estimates

Removing fluoride from public drinking water may lead to millions more cavities in US children, study estimates

CNN30-05-2025
Water availabilityFacebookTweetLink
Follow
The longstanding public health practice of adding fluoride to public drinking water systems in the United States is facing new challenges and bans in some places, and experts have warned that the change would come with significant costs – both to the health of children and the health care system.
A new modeling study, published Friday in JAMA Health Forum, estimates that removing fluoride from public water in the US would lead to 25.4 million excess decayed teeth in children and adolescents within five years, along with $9.8 billion in health care costs. After 10 years, these impacts would more than double to nearly 54 million excess decayed teeth and $19.4 billion in costs.
That translates to one additional decayed tooth for every three children in the US – but the costs wouldn't be spread evenly, said Dr. Lisa Simon, an internal medicine physician with Brigham and Women's Hospital and co-author of the new study.
'We know that the people who have the most benefit from fluoride are people who otherwise struggle to access dental care,' says Simon, who has been researching dental policy for a decade. 'When we think about those 25 million decayed teeth, they're much more likely to appear in the mouths of children who are publicly insured by Medicaid or come from otherwise low-income families.'
Fluoride is a mineral that can be found naturally in some foods and groundwater. It can help prevent tooth decay by strengthening the protective outer layer of enamel that can be worn away by acids formed by bacteria, plaque and sugars in the mouth. Adding fluoride to public water systems started in the US in 1945 and has been hailed by the US Centers for Disease Control and Prevention as one of the 10 greatest health interventions in America in the 20th century
In 2022, close to two-thirds of the US population was served by community water systems that had fluoride added to them, according to CDC data. But US Department of Health and Human Services Secretary Robert F. Kennedy Jr. said in April that he would tell the CDC to stop recommending that fluoride be added to public drinking water, and lawmakers in two states – Utah and Florida – have banned the practice this year.
To estimate the effects of removing fluoride from community water, Simon and co-author Dr. Sung Eun Choi from the Harvard School of Dental Medicine assessed clinical oral health data from the National Health and Nutrition Examination Survey to create a nationally representative sample of US children.
At baseline, the data showed that about 1 in 5 children between the ages of 2 and 5 were estimated to have dental caries, a chronic infectious disease involving tooth decay and cavities, along with more than half of children ages 6 to 12 and more than 57% of teenagers. But removing fluoride would raise those prevalence rates by more than 7 percentage points, the researchers found.
'This is a huge cost for our country and it's all avoidable. There is no better replacement for the time-tested, doctor trusted use of fluoride in community water programs,' Dr. Brett Kessler, president of the American Dental Association, said in a statement. 'No amount of political rhetoric or misinformation will change that good oral health depends on proper nutrition, oral hygiene and optimally fluoridated water, or fluoride supplements if community water programs lack fluoride.'
On the campaign trail last fall, Kennedy called fluoride 'industrial waste' and claimed that exposure has resulted in a wide variety of health problems, including cancer – claims that both the American Cancer Society and the CDC have disagreed with. And in April, HHS and the US Environmental Protection Agency announced that they would study the potential health risks of fluoride in drinking water – a review centered around a government study from last year concluding that higher levels of fluoride are linked to lowered IQ in children.
In the new modeling study, researchers found that only about 1.5% of US children in 2016 had exposure to this excess level of fluoride – considered to be above 1.5 milligrams per liter – that posed risk for fluorosis, a condition that leaves streaks or spots on teeth, or other harms. Meanwhile, about 40% of US children had access to optimal fluoride levels that effectively prevent tooth decay – between 0.6 and 1.5 milligrams per liter – while about 46% had access to even lower levels.
The authors of the new study did not assess the neurocognitive effects of fluoride because 'current federal guidance does not find an association' at the levels used in public drinking water. They found that removing fluoride would only help prevent about 200,000 cases of fluorosis over five years.
Tooth decay can mean a lot of things, Simon said, but their model was picking up cases that would likely need at least a filling along with severe cavities that could turn into a root canal or a tooth extraction – the costs of which would be borne by families, insurers and the government.
'Talking about money, which is really important, is only one way to measure that cost,' Simon said. 'It's also a cost in terms of children being in pain, children not being able to eat, children missing school or not being able to pay attention in school because their teeth hurt, parents missing work, children losing teeth that are supposed to stay with them for their entire lives, and those children growing into older adults who are more likely to be missing teeth with all of the health consequences that entails.'
Forecasts in the new modeling study mirror real-life impacts that were measured in other parts of the world after fluoride was removed from drinking water. Calgary, Alberta, stopped putting fluoride in its water in 2011, and a study found that children there had more cavities than those in cities that kept fluoride. Calgary will resume fluoridation this year.
Simon worries the effects in the US might be even greater because of health inequities that are especially pronounced in the dental care system.
'We've had fluoridated water for so long and it's worked so well that we've stopped appreciating the amazing things it's done,' she said. 'When something has been a success story for 80 years … you don't know which kid never got a cavity because they were exposed to fluoride, and we don't know which older adults aren't wearing dentures because of that.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

Yahoo

time24 minutes ago

  • Yahoo

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs

FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio

Donald Trump announces trade deal with Japan
Donald Trump announces trade deal with Japan

Yahoo

time24 minutes ago

  • Yahoo

Donald Trump announces trade deal with Japan

US President Donald Trump has announced a trade framework with Japan, placing a 15% tax on goods imported from that nation. 'This Deal will create Hundreds of Thousands of Jobs – There has never been anything like it,' Mr Trump posted on Truth Social, adding that the United States 'will continue to always have a great relationship with the Country of Japan'. The president said Japan would invest 'at my direction' 550 billion dollars into the US and would 'open' its economy to American cars and rice. The 15% tax on imported Japanese goods is a meaningful drop from the 25% rate that Mr Trump, in a recent letter to Japanese Prime Minister Shigeru Ishiba, said would be levied starting on August 1. Early Wednesday, Mr Ishiba acknowledged the new trade agreement, saying it would benefit both sides and help them work together. With the announcement, Mr Trump is seeking to tout his ability as a dealmaker — even as his tariffs, when initially announced in early April led to a market panic and fears of slower growth that for the moment appear to have subsided. Key details remained unclear from his post, such as whether Japanese-built cars would face a higher 25% tariff that Mr Trump imposed on the sector. But the framework fits a growing pattern for Mr Trump, who is eager to portray the tariffs as a win for the US. His administration says the revenues will help reduce the budget deficit and more factories will relocate to America to avoid the import taxes and cause trade imbalances to disappear. The wave of tariffs continues to be a source of uncertainty about whether it could lead to higher prices for consumers and businesses if companies simply pass along the costs. The problem was seen sharply on Tuesday after General Motors reported a 35% drop in its net income during the second quarter as it warned that tariffs would hit its business in the months ahead, causing its stock to tumble. As the August 1 deadline for the tariff rates in his letters to world leaders is approaching, Mr Trump also announced a trade framework with the Philippines that would impose a tariff of 19% on its goods, while American-made products would face no import taxes. The president also reaffirmed his 19% tariffs on Indonesia. The US ran a 69.4 billion dollar trade imbalance on goods with Japan last year, according to the Census Bureau. America had a trade imbalance of 17.9 billion dollars with Indonesia and an imbalance of 4.9 billion dollars with the Philippines. Both nations are less affluent than the US and an imbalance means America imports more from those countries than it exports to them. The president is set to impose the broad tariffs listed in his recent letters to other world leaders on August 1, raising questions of whether there will be any breakthrough in talks with the European Union. At a Tuesday dinner, Mr Trump said the EU would be in Washington on Wednesday for trade talks. 'We have Europe coming in tomorrow, the next day,' Mr Trump told guests. The president earlier this month sent a letter threatening the 27 member states in the EU with 30% taxes on their goods to be imposed starting on August 1.

Hilton beats earnings expectations despite modest RevPAR decline
Hilton beats earnings expectations despite modest RevPAR decline

Yahoo

time24 minutes ago

  • Yahoo

Hilton beats earnings expectations despite modest RevPAR decline

-- Hilton Worldwide Holdings Inc. reported second-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of $2.20 surpassing the consensus estimate of $2.03. Revenue for the quarter came in at $3.14 billion, slightly above the analyst forecast of $3.1 billion. The hotel giant's system-wide comparable RevPAR (revenue per available room) declined 0.5% on a currency neutral basis compared to the same period in 2024, attributed to modest occupancy declines that were partially offset by ADR (average daily rate) gains. Despite this top-line weakness, management and franchise fee revenues increased 7.9% YoY. Hilton's stock edged up 0.6% following the announcement. "We continued to demonstrate the power of our resilient business model as we delivered strong bottom line results in the quarter, even with modestly negative top line performance given holiday and calendar shifts, reduced government spending, softer international inbound business and broader economic uncertainty," said Christopher Nassetta, President & CEO of Hilton. For the full year 2025, Hilton projects adjusted earnings per share between $7.83 and $8.00, compared to the analyst consensus of $7.96. The company expects system-wide RevPAR to be flat to up 2.0% on a comparable and currency neutral basis versus 2024. Hilton's development pipeline reached a record 510,600 rooms as of June 30, up 4% from the previous year. The company added 26,100 rooms to its system during the quarter, resulting in 22,600 net additional rooms and contributing to net unit growth of 7.5% YoY. Related articles Hilton beats earnings expectations despite modest RevPAR decline Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett If Powell goes, does Fed trust go with him? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store